Cancer Diagnostic Markers Top Celera's Agenda Following Sequencing Coup
This article was originally published in The Gray Sheet
Executive Summary
Colon, pancreatic and breast cancers are initial disease areas for which Celera Genomics plans to develop diagnostic markers. In support of the effort, Celera will expand its high-throughput screening capability with the construction of a proteomics facility at the firm's Rockville, Maryland headquarters this spring.